Monga Varun, Maliske Seth M, Perepu Usha
Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa Carver College of Medicine, Iowa City, IA 52242 USA.
Aspirus Wausau Hospital Regional Cancer Center, 333 Pine Ridge Blvd, Wausau, WI 54401 USA.
Thromb J. 2017 Jul 3;15:18. doi: 10.1186/s12959-017-0141-5. eCollection 2017.
Evans syndrome (ES) is a rare disease characterized by simultaneous or sequential development of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) with or without immune neutropenia. Splenectomy is one of the treatment options for disease refractory to medical therapy. Venous thromboembolism (VTE) following splenectomy for hematological diseases has an incidence of 10%.
Here we describe a case report of a young patient hospitalized with severe hemolytic anemia with Hgb 4.8 g/dl. He developed thrombocytopenia with platelet nadir of 52,000/mm, thus formally diagnosed with ES. He failed standard medical therapy. He underwent splenectomy and had a fatal outcome. Autopsy confirmed the cause of death as pulmonary embolism (PE).
This case report and review of the literature highlight important aspects of the association between VTE, splenectomy, and hemolytic syndromes including the presence of thrombocytopenia. The burden of the disease is reviewed as well as various pathophysiologic mechanisms contributing to thromboembolic events in these patients and current perioperative prophylactic anticoagulation strategies. Despite an advancing body of literature increasing awareness of VTE following splenectomy, morbidity and mortality remains high. Identifying high risk individuals for thromboembolic complications from splenectomy remains a challenge. There are no consensus guidelines for proper perioperative and post-operative anti-coagulation. We encourage future research to determine which factors might be playing a role in increasing the risk for VTE in real time with hope of forming a consensus to guide management.
伊文斯综合征(ES)是一种罕见疾病,其特征为自身免疫性溶血性贫血(AIHA)和免疫性血小板减少症(ITP)同时或先后发生,可伴有或不伴有免疫性中性粒细胞减少。脾切除术是药物治疗难治性疾病的治疗选择之一。血液系统疾病脾切除术后静脉血栓栓塞(VTE)的发生率为10%。
在此,我们描述一例年轻患者的病例报告,该患者因严重溶血性贫血住院,血红蛋白为4.8 g/dl。他出现血小板减少,血小板最低点为52,000/mm,因此被正式诊断为ES。他的标准药物治疗失败。他接受了脾切除术,最终死亡。尸检证实死亡原因是肺栓塞(PE)。
本病例报告及文献综述强调了VTE、脾切除术和溶血性综合征之间关联的重要方面,包括血小板减少的存在。回顾了疾病负担以及导致这些患者血栓栓塞事件的各种病理生理机制和当前的围手术期预防性抗凝策略。尽管有越来越多的文献提高了对脾切除术后VTE的认识,但发病率和死亡率仍然很高。识别脾切除术后血栓栓塞并发症的高危个体仍然是一项挑战。对于适当的围手术期和术后抗凝没有共识性指南。我们鼓励未来开展研究,以确定哪些因素可能实时增加VTE风险,希望形成共识以指导管理。